ANDS in Canada: Bioequivalence Requirements, the Canadian Reference Product Rule, and Common Submission Pitfalls

Every year, Health Canada’s Therapeutic Products Directorate (TPD) issues Notice of Deficiency letters to generic drug sponsors for the same cluster of mistakes. The most consistent one? Submitting bioequivalence data generated against a reference product that was never authorized for sale in Canada.

That single oversight can derail a submission and extend your timeline by months. If you’re preparing an Abbreviated New Drug Submission (ANDS) for the Canadian market — or supporting one as a CRO — understanding where the Canadian process diverges from its US counterpart is essential. The differences are real, they’re consequential, and they’re often underestimated by teams whose regulatory instincts were developed south of the border.

What Is an ANDS and When Do You Need One?

An ANDS is the regulatory pathway for generic drugs in Canada, governed by Section C.08.002.1 of the Food and Drug Regulations (FDR). It allows a sponsor to rely on the established safety and efficacy record of an already-approved innovator product, provided the generic formulation is shown to be pharmaceutically equivalent and bioequivalent to that innovator.

The pathway differs from a New Drug Submission (NDS) in one fundamental way: an NDS requires independent clinical evidence of safety and efficacy. An ANDS substitutes bioequivalence data for that clinical evidence. That substitution is only valid if your study is methodologically sound — and conducted against the right reference product.

Done correctly, an ANDS is genuinely efficient. It removes the requirement for Phase II and Phase III clinical trials, saving years of development time and tens of millions of dollars. Done carelessly, it becomes a deficiency cycle that outlasts a properly designed program by a wide margin.

The Canadian Reference Product Rule — More Restrictive Than You Think

Here’s where Canadian regulatory strategy diverges sharply from what US-based teams expect.

In the United States, FDA allows ANDA sponsors to reference the Reference Listed Drug (RLD) — typically the innovator, sometimes an authorized generic. Health Canada is more specific: your ANDS must reference the Canadian Reference Product (CRP) — the product that holds a valid Notice of Compliance (NOC) in Canada and is actively marketed here.

Using a US-approved reference product, even if it’s the identical innovator formulation, is not acceptable. Health Canada requires that the CRP be currently marketed in Canada or have been recently marketed. If the innovator has been withdrawn from the Canadian market, you’ll need a pre-submission discussion with the TPD before designing your bioequivalence program. That conversation should happen before you spend a dollar on study design.

This matters enormously for cross-border CRO/CMO collaborations. Teams that routinely conduct bioequivalence studies for FDA submissions often assume those studies automatically satisfy Health Canada. They don’t. The CRP may carry a different strength, a different excipient profile, or a different formulation than its US counterpart. Your program needs to reflect the Canadian product — not the US one.

Confirm the CRP’s current market status using Health Canada’s Drug Product Database (DPD) before initiating any studies. It’s a five-minute check that can save a six-month deficiency.

Bioequivalence Study Design: What Health Canada Actually Requires

Health Canada’s guidance document Conduct and Analysis of Comparative Bioavailability Studies sets out the core requirements for in vivo bioequivalence studies. For most immediate-release oral solid dosage forms, a standard 2-period, 2-sequence crossover design in healthy adult volunteers is expected.

The bioequivalence criterion is consistent with international practice: the 90% confidence interval of the geometric mean ratio (test/reference) for both AUC(0-t) and Cmax must fall within 80.00–125.00%. Both parameters must meet this criterion simultaneously — meeting it for AUC alone isn’t sufficient.

Several design elements catch sponsors off guard:

Subject numbers. Health Canada doesn’t mandate a single fixed number, but statistical power requirements and the variability characteristics of most drug substances typically demand at least 12 evaluable subjects as a floor — and 24–36 subjects is common in practice to account for dropouts and high intra-subject variability. Studies arriving at the TPD with fewer than 12 evaluable subjects face immediate scrutiny.

Washout period. Crossover studies must include a washout period of at least 5 elimination half-lives of the reference product. For drugs with pharmacologically active metabolites, the half-life of the metabolite governs the washout calculation — not just the parent compound. This is a minimum, not a suggestion.

Fasting vs. fed conditions. Fasting studies are the default for immediate-release solid oral forms. Fed-state studies are required for modified-release products and for drugs with clinically significant food effects. If the Canadian labeling of the innovator specifies administration with food, a fed-state study is typically required alongside the fasting study.

GCP compliance. All bioequivalence studies submitted in support of an ANDS must comply with ICH E6(R2) Good Clinical Practice. Health Canada reviews source data verification records and site audit trails with increasing attention. A study conducted outside a GCP-compliant framework — even if the pharmacokinetic results are clean — will trigger a deficiency regardless of the outcome data.

BCS-Based Biowaivers: When You Can Skip the In Vivo Study

Not every drug requires a human pharmacokinetic study. Health Canada accepts Biopharmaceutics Classification System (BCS)-based biowaivers for certain drug substances, provided the conditions in its biowaiver guidance are met.

The BCS categorizes drug substances across 4 classes based on aqueous solubility and intestinal permeability:

• Class I: High solubility, high permeability
• Class II: Low solubility, high permeability
• Class III: High solubility, low permeability
• Class IV: Low solubility, low permeability

Health Canada accepts biowaiver applications for Class I and Class III drugs, with different criteria for each. For Class I substances, both the test and reference product must demonstrate rapid dissolution — typically ≥85% dissolved within 30 minutes under specified pharmacopoeial conditions. For Class III, the criteria are considerably more stringent: essentially identical qualitative and quantitative composition is expected, since permeability (not dissolution) is the rate-limiting step.

Biowaivers are categorically unavailable for narrow therapeutic index drugs, drugs exhibiting non-linear pharmacokinetics across the therapeutic range, or drugs intended for site-specific absorption within the GI tract. If your compound falls into these categories, in vivo bioequivalence data is non-negotiable — there’s no workaround.

What Health Canada Reviews Beyond the Bioequivalence Data

The bioequivalence study is necessary but not sufficient. A complete ANDS package submitted to the TPD includes clinical, pharmaceutical, and quality modules — and deficiencies arise across all three.

Health Canada will also review:

• Comparative dissolution profiles tested across at least three pH conditions: pH 1.2, 4.5, and 6.8. Sponsors who submit dissolution data from a single condition routinely receive a request for additional data.
• In vitro pharmaceutical equivalence documentation confirming the test and reference share the same dosage form, route of administration, and equivalent strength.
• Method validation data for all analytical procedures used in release testing and stability studies.
• Stability data supporting the proposed shelf life under ICH Q1A conditions.
• Manufacturing site GMP compliance, confirmed either through a Health Canada inspection or recognition under a Mutual Recognition Agreement (MRA) with a partner authority.

That last item deserves emphasis. Under Division 2 of Part C of the FDR, all manufacturers producing drugs for sale in Canada must comply with Health Canada’s GMP requirements — including contract manufacturers. If your CMO isn’t already on Health Canada’s list of approved sites or hasn’t been inspected by a recognized MRA partner authority, Health Canada may conduct a pre-licence inspection before issuing a Notice of Compliance. This step can add months to an already long review timeline if it isn’t anticipated.

Health Canada targets a 300 business-day review window for standard ANDS submissions. In practice, a Notice of Deficiency — common even for well-prepared dossiers — can push total elapsed time to 18 months or beyond. Front-loading the submission with complete, well-organized data is the most effective timeline management strategy available to sponsors.

The Most Common Deficiencies — And How to Prevent Them

After working through numerous ANDS programs and reviewing the patterns that recur in Health Canada deficiency letters, a handful of categories account for the large majority of issues:

Wrong reference product. Confirm the CRP’s market status before study initiation. This is the single most preventable deficiency in the ANDS pathway.

Insufficient dissolution comparisons. Three pH conditions are expected. For modified-release products, additional conditions reflecting the product’s release mechanism are typically required.

Incomplete clinical study reports. Health Canada follows ICH E3 report structure, supplemented by its own comparative bioavailability guidance. Missing individual subject data listings, absent statistical analysis tables, or undocumented GCP compliance statements are common deficiency triggers.

GMP gaps at the contract site. Resolve manufacturing site compliance status well before filing. Discovering a GMP gap after submission is far more disruptive than addressing it during pre-submission planning.

Unjustified specification limits. Dissolution acceptance criteria must be justified by the bioequivalence and dissolution data. Limits set at values that wouldn’t distinguish the product from the reference under relevant conditions invite requests for detailed justification.

What to Do Before You Start

The ANDS pathway is genuinely efficient when the groundwork is done properly. Generic sponsors who treat it as a transplant of their US ANDA program — without accounting for the CRP rule, the specific dissolution requirements, or the GMP verification step — consistently spend more time in deficiency review than the original submission window would have required.

The most productive investment at program initiation is a formal regulatory strategy review: confirm the CRP, verify the CMO’s GMP standing with Health Canada, and determine whether a BCS biowaiver is viable for your compound. That review takes weeks. Correcting a deficient submission takes considerably longer.

---

Written by Nour Abochama, Quality & Regulatory Advisor, Androxa. Learn more about our team

Talk to our team about Health Canada compliance Contact us

Related from our network

• ISO 17025-accredited pharmaceutical testing for Canadian submissions — Qalitex Laboratories provides dissolution testing, method validation, and stability studies in support of Health Canada drug dossiers.
• EU regulatory strategy and GMP consulting for pharmaceutical manufacturers — Care Europe supports EMA submissions and EU GMP compliance for manufacturers expanding beyond the Canadian market.